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ADVANCES IN TUMOR-TARGETED THERAPY USING NANOMEDICINE  
 
Divya Karukonda 
July 31st, 2017 
 
 Despite continuous improvement and significant progress made in 
diagnostic and therapeutic approaches for cancer, it is still the leading cause of 
death worldwide. Although conventional chemotherapy has made significant 
advances in improving patient survival the indiscriminate destruction of normal 
cells leads to severe side effects and poor clinical outcomes. Thus, there is a 
need for effective delivery of drugs to the tumor site avoiding normal tissues to 
reduce toxicity in the rest of the body. For this reason, a novel multidisciplinary 
field called Nanotechnology has evolved in recent years and advances in this 
field have contributed to the development of nanoscale materials to overcome 
the lack of specificity of conventional chemotherapeutic agents for optimized 
cancer therapy. Nanoparticles can be designed to preferentially target the tumor 
site and deliver high drug payloads by either passive or active targeting. Passive 
targeting exploits the preferential drug accumulation in tumor cells through 
enhanced permeability and retention (EPR) effect. On the other hand, active 
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targeting uses functionalized nanoparticles to carry a drug to the specific site. 
This targeting strategy is becoming a new standard in cancer treatment. A 
selective and tumor site-specific treatment can be achieved by using various 
ligands such as aptamers, antibodies, peptides, and small molecules. Targeting 
nanocarriers serve as a highly promising strategy for effective cancer treatment, 
as shown by encouraging results in many recent studies. This thesis highlights 
the diversity of nanoparticle types, targeting mechanisms and active targeting 
strategies. I will also discuss an emerging field of nano drug delivery using 
biological nanovesicles called exosomes. Finally, I will discuss the current clinical 
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Cancer and therapy 
Cancer is the leading cause of death worldwide despite continuous 
improvement in the therapeutic strategies and early detection. Cancer incidence 
has been increasing in recent decades and American Cancer Society estimates 
that the number of new cases are projected to increase by 50% worldwide from 
14 million in 2012 to 22 million by 2030. In 2017, 1,688,780 new cancer cases 
and 600,920 cancer deaths are estimated to occur in the United States (1). 
Cancer is a complex disease caused by uncontrolled growth and division of 
abnormal cells due to gene mutations. As a result of mutational changes, cancer 
cells exhibit certain characteristics including proliferation, resistance to signals 
that inhibit their growth and resistance to apoptotic signals that cause cell death, 
which make it difficult to treat the disease (2). Cancer cells interact with the 
microenvironment to acquire different capabilities during the multistep 
development of a tumor particularly, overcome immune response for survival, 
activate stromal cells to inappropriately promote angiogenesis, and invade 
through tissues, and metastasize to distant organs induced by tumor 
microenvironment components (3).  
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Standard treatment for cancer includes combinations of surgery, radiation 
and chemotherapy (chemo). Other treatment options include hormonal therapy 
and targeted therapy (including immunotherapy such as monoclonal antibody 
therapy). The choice of therapy depends upon the location, grade of the tumor 
and the stage of the disease. Over the last decade a number of potent anticancer 
drugs have been developed with various mechanisms of action such as blocking 
nucleic acid biosynthesis, interfering with gene transcription, causing cell cycle 
arrest, inducing apoptosis, and inhibiting angiogenesis (4). 
Limitations of conventional therapy 
Conventional chemotherapy that targets DNA is very effective and has 
resulted in improved survival rates of cancer patients. However, it has several 
limitations such as poor solubility, poor selectivity, non-specific drug distribution, 
fast clearance rate, systemic toxicity, multi-drug resistance, cancer reoccurrence, 
off- target effects along with severe side effects (5).  These limitations pose a 
significant challenge in the effective treatment of cancer. Most of the 
chemotherapeutics in the market at present such as doxorubicin, paclitaxel, and 
vincristine have less selectivity toward the target and are systemically distributed 
without selective localization to site of tumor. Thus, higher doses are required to 
achieve pharmacological levels at the target site and this leads to increased 
toxicity to the normal tissues causing severe side effects. An example of this is 
anthracycline drug causing cardiotoxicity, severe in some cases (6). In order to 
avoid toxic side effects, chemo drugs are often given at lower doses, which are 
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less than the required doses resulting in subsequent failure of therapy 
accompanied by development of drug resistance and metastatic disease. 
Hence, eradication of cancer still remains a major problem due to its 
heterogeneous nature and inability of chemotherapeutics to reach the tumor site 
without damaging the normal healthy tissues.         
Effective solution  
Delivering drug to the disease site is a major hurdle for many of the 
diseases including cancer. Because of the limitations noted above there has 
been enormous interest in developing an innovative technologies that can deliver 
drug at the target site. Over a century ago Paul Ehrlich introduced a concept of 
“Magic Bullet” for targeted drug delivery (7). It has two entities: the first one is 
that the drug should recognize the target and the second is that the drug should 
provide therapeutic action at the targeted site. Cell- or tissue-specific targeting is 
achieved by encapsulating a  drug and targeting moiety in an appropriate 
pharmaceutical carrier which is the revised version of Ehrlich magic bullet (8). 
Nanoparticles can be designed including all three entities and could be used as 
both therapeutics and diagnostics. A number of studies show that most of the 
limitations of conventional drugs can be overcome by nanotechnology and that 
nanoparticles as carriers have huge potential to overcome the limitations of 
chemotherapeutics (9, 10). 
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Nanotechnology in cancer 
Nanotechnology involves use of nanometer scale materials and systems 
by controlling the matter on a level of atomic, molecular and supramolecular 
scale. (11-14). The size of nanomaterials is around 10-100 nm and their unique 
size is ideal for increased solubility, oral bioavailability, rate of dissolution, 
surface area, high therapeutic loading and rapid onset of therapeutic action upon 
intracellular uptake (15). In contrast, conventional drugs are rapidly cleared from 
the body, reducing the amount of drug at the tumor site (16). Nanocarriers with 
drugs incorporated increase the half-life of drugs in circulation, allowing a greater 
amount of drug to reach the target site (11). Anticancer drugs in nano 
formulations exhibit enhanced therapeutic index due to improved 
pharmacokinetics, tissue distribution, and enhanced accumulation or release of 
the drug at the tumor site (17). The nano-sized particles exhibit more 
extravasation and permeability into tumor tissues with leaky vasculature in 
contrast to neo-vasculature of normal tissues, minimizing off-target toxicities, and 
enhancing delivery to site of action. Their small size also facilitates oral, nasal, 
ocular, and parenteral routes of drug administration. Thus, nanoparticle drug 
delivery systems can serve as the successful tools to anticancer therapy. 
A variety of nanostructures have been investigated such as synthetic 
biodegradable polymers, lipids (liposomes), mesoporous silica nanoparticles 
(MSNs), micelles, quantum dots, carbon nanotubes, and gold nanoparticles for 
the treatment of cancer (18-22). A summary of their properties is presented in 
Table (1) (23) 
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Liposomes, first discovered by Dr. Alec Bangham in 1961 (24), and are 
extensively explored as the  nanocarriers for the targeted drug delivery. A 
separate field of liposomal technology research was started by the approval of 
first nano drug - DoxilR which is a big hit in the market. The   field of liposomal 
literature is only focused on liposomes without the term nano until 2000. 
Liposomes are closed vesicles surrounded by a lipid bi-layer membrane 
composed of phospholipids. Their hydrophilic core can be used for the 
entrapment and delivery of water-soluble drugs. These vesicles are uni- or muti-
lamellar and have a potential to carry both hydrophilic and lipophilic molecules 
entrapped within the lipid bilayer. Availability of liposomes with diverse properties 
makes them the most intelligent drug carrier systems available (25) 
Polymeric micelles are nano-sized vectors that contain amphiphilic block 
copolymers which assemble to form nanoscopic core-shelled colloidal structures 
termed micelles. Their advantage is in trapping drugs physically within the 
hydrophobic cores or linking drugs covalently to component molecules of the 
micelle. Additionally, they proved to be an excellent novel drug delivery system 
due to their high stability in physiological conditions, high loading capacity, and 
high accumulation of drug at target site (26). 
Dendrimers are a class of polymeric materials. First discovered in the 
early 1980’s by Donald Tomalia and colleagues (27), these  hyper-branched, 
tree-like, structured polymeric molecules originate from the Greek word dendron, 
meaning a tree. As the chains growing from the core molecule become longer 
and more branched, they adopt a globular structure. Dendrimers become 
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densely packed as they extend out to the periphery, forming a closed membrane-
like structure. Their sizes range between 1.9 nm and 4.4 nm, the smallest 
nancoarriers so far developed. Dendrimer-drug interactions or drug loading in 
dendrimers may be achieved by various approaches: simple encapsulation in the 
interior of dendrimers (illustrated in Fig. 1) involves electrostatic interactions and 
covalent conjugations to the surface of the dendrimers. They serve as an ideal 
carrier for drug delivery due to several advantages, for example, they can be 
modulated for target-specific drug delivery, have a defined molecular weight, are 
of a small size, and have good entrapment efficiency , thus offering a good 
surface for functionalization (28). 
The general term nanoparticles (NPs), describes a wide range of nano 
systems including organic polymeric NPs, composed of synthetic or natural 
polymers or proteins (i.e, albumin), solid lipid nanoparticles comprising of 
physiological lipids, as well as inorganic NPs such as semiconductor NPs, iron 
oxide NPs, quantum dots and gold NPs (29) 
Polymeric nanoparticles are widely investigated nanoparticles in clinical 
trials, and received much attention after the initial work of Langer and Folkman in 
1976 (30). Because of their biodegradability, biocompatibility, high drug loading, 
stability and flexibility, polymeric nanoparticles are used for controlled release of 
drug. They usually consist of a general core-shell structure and are also 
subdivided into various categories according to their basic chemical and core 
shell composition and their morphology, including nanocapsules (NCs) and 
nanospheres (NSs). Nanocapsules are hollow spherically-shaped vesicular 
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particles, where the drug is confined to a hollow core, usually composed of oil 
droplets, which is surrounded by a polymeric shell or membrane (31). 
Nanospheres are solid colloidal matrix systems, ideally uniform in their core-shell 
polymer partition, where a drug is dispersed or dissolved in the polymer matrix 
(32) (Fig. 1). Various synthetic and natural polymers currently being investigated 
for the design and potential applications of nanoparticles are polyethylene glycol 
(PEG), poly lactic acid (PLA) and poly D,L-lactide co-glycolide) (PLGA) and their 
copolymers PEG-PLA, PEG-PGA, PLGA and PEG-PLGA; these nanocarriers are 





Figure 1. Basic structure of nanoparticles used for cancer therapy entrapped 
with drug (Source : With permission from Katayoun et al., 2015 Active-targeted 
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Despite the variety of nanomaterials designed for tumor targeting, only a 
limited number of formulations are clinically approved (Table 4). Treatment 
efficacy is often impeded by nonspecific drug distribution and lack of specificity to 
the target tissue site. Ideally, enhancing drug accumulation at the site of tumor 
will lower the systemic exposure and result in a more efficient and patient-friendly 
treatment. Several drug-targeting strategies can be engaged to reach target 
tissues. These include active and passive targeted drug delivery which are 
described in Chapter II. Targeted delivery of anticancer agents is a rapidly 
evolving and is a highly promising field of research.  Indeed, targeted drug 
delivery potentially increases the local concentration of the fraction of the 
systemically administered dose reaching the tumor site, minimizing toxicity to the 
adjacent healthy cells. A particular focus has been the active targeting of nano 
drug delivery systems for the treatment of cancer because of the discovery of 
new molecular targets, a deep understanding of biology of cancer, and the failure 
of conventional treatment. Together, these lead to the enormous interest in 








DRUG TARGETING MECHANISMS 
The key to success in cancer treatment is the therapeutic concentration at 
the tumor site. The concentration of therapeutic agent reaching the tumor tissue 
should be precise after crossing and penetrating all the biological barriers in the 
body. Once the drug is at the active site, it should selectively destroy the cancer 
cells, avoiding healthy tissues to reduce adverse effects and toxicity. To achieve 
these goals, nanoparticle drug delivery systems use the characteristics of the 
disease tissue to target their payloads. The drug-loaded nanoparticles reach the 




Figure 2. Passive and active targeting to enhance permeability and retention. , 
Nanoparticles (NPs) can be passively extravasated through leaky 
vascularization, allowing their accumulation at the tumor region (A). In this case, 
drugs may be released in the extracellular matrix and then diffuse throughout the 
tissue or tumor. Active targeting (B) can enhance the therapeutic efficacy of 
drugs by increasing accumulation and cellular uptake of NPs through receptor-
mediated endocytosis. (Source: With permission from Suwassa et al., A focus on 
nanoparticles as drug delivery system) (41). 
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Passive drug Targeting 
Nanoparticles drug delivery systems use pathophysiological 
characteristics of the tumor vasculature through the enhanced permeability and 
retention (EPR) effect. The EPR concept was originally described by Maeda et 
al., 1986 and this theory is based on the characteristics of tumor vasculature of 
leaky blood vessels and lack of lymphatic drainage (42). This allows the diffusion 
of longer circulating nanoparticles to the tumor site, avoiding health tissues, and 
thereby being selectively site-specific (43, 44). Most passive-targeting 
nanoparticles are surface-coated with PEG for biocompatibility, e.g., SP1049C, 
Genexol- PM, NK911 (45, 46) in early clinical trials for treating various types of 
cancer. 
However, high heterogeneity of the EPR effect in tumors which varies 
from patient to patient and within same subject is a significant limitation to this 
strategy (47). The determination of precise impact of the EPR effect on 
nanoparticle accumulation in tumor tissues becomes difficult since a variety of 
parameters including size, shape, and zeta potential of nanoparticles are 
involved in this process. Only a small part of injected dose is accumulated in 
target cancer tissues which becomes a significant restriction in passive drug 
strategy (42). In view of these limitations of passive targeting a considerable 





Active drug Targeting:  
Active drug targeting is aimed at delivery of active drug selectively to the 
tumor site. Active drug-delivery strategies comprise use of a targeting ligand or 
moiety attached on the surface of nanocarrier, which recognizes and enables the 
nanoparticle to bind to receptors (tumor-specific epitope) overexpressed on 
tumor cells. These receptors serve as tumor markers which are either expressed 
at lower levels or essentially not expressed on normal cells. The interaction 
between ligand and receptor is affected by binding affinity and selectivity of the 
targeting unit and by the targeted receptor’s capacity (48). Receptor levels 
depend not only on synthesis and stability, but also on recycling rate after 
receptor activation and internalization (49). Hence the binding affinity of the 
targeting ligand and number of ligand units conjugated and decorated on the 
surface are the important factors affecting targeting efficiency. To target the 
nanoparticles effectively to the desired site it is essential to have sufficient 
quantity of ligands/targeting moieties along with high affinity binding to cell 
surface receptors (50). Therefore, the most important feature of the targeting 
ligand is to induce receptor-mediated endocytosis causing the internalization of 
the drug carrier into the desired tumor tissue specific intracellular site (51, 52).  
Currently there are many approaches available for active targeting to 
tumor cells. All the ligands that can be attached to the nanoparticles can serve 
as targeting moieties. There are wide variety of tumor-targeting moieties 
including small molecules, peptides, monoclonal antibodies, aptamers and 
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nucleic acids which specifically recognize receptors overexpressed on tumor cell 












TYPES OF LIGANDS FOR ACTIVE TARGETING 
The identity and characteristics of the targeting ligands are extremely 
important for circulation time, cellular uptake, affinity, and extravasation. 
Targeting ligands can be broadly classified as proteins (mainly antibodies and 
their fragments), nucleic acids (aptamers), or other small molecules (peptides, 
vitamins, and carbohydrates). 
Monoclonal Antibodies (mAb) 
Targeting cancer with a mAb was described by Milstein in 1981 (53). 
mAbs bind to a receptor on the cell surface to induce several antibody-based 
anticancer mechanisms including antibody-dependent cellular cytotoxicity 
(ADCC) and complement-dependent cellular toxicity (CDC) (54, 55). The 
feasibility of antibody-based tissue-targeting has been clinically demonstrated 
with 17 different mAbs approved by the US Food and Drug Administration (FDA) 
(56). The mAb rituximab (Rituxan) was approved in 1997 for treatment of 
patients with non-Hodgkin's lymphoma — a type of cancer that originates in 
lymphocytes (57). A year later, Trastuzumab (Herceptin), an anti-HER2 mAb 
that binds to ErbB2 receptors, was approved for the treatment of HER2+ breast 
cancer (58). The first angiogenesis inhibitor for treating colorectal cancer, 
Bevacizumab (Avastin), an anti-VEGF mAb that inhibits the growth of new blood 
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vessels, was approved in 2004 (59). Today, over 200 delivery systems based on 
antibodies or their fragments are in preclinical and clinical trials (60). Recent 
developments in the field of antibody engineering have resulted in the 
production of antibodies that contain animal and human origins such as chimeric 
mAbs, humanized mAbs (those with a greater human contribution), and 
antibody fragments. However, there are several limitations to this approach 
including immunogenicity, large size, and cost of mAb synthesis, rapid 
clearance, and environmental factors. The use of antibody fragments like Fab 
and single chain variable fragments reduce the immunogenicity by keeping high 
antigen binding specificity (52). 
Aptamers 
Aptamers are another emerging class of targeting ligands which are short 
single-stranded RNA or DNA sequences of oligonucleotides that can be 
designed as targeting ligand capable of binding to target receptors on the 
surface of cancer cells with high selectivity and affinity (61). They form unique 
three-dimensional structures with high ligand binding specificity needed for 
target affinity. They are small size (~15 KDa), less immunogenic when 
compared to antibodies, and can be chemically synthesized. Several aptamers 
have been developed to bind specifically to receptors on cancer cells, and can 
be considered suitable for nanoparticle-aptamer conjugate therapy (62). 
Docetaxel (Dtxl)-encapsulated nanoparticles with aptamer (targets the antigen 
on the surface of prostate cancer cells) functionalized surface were delivered 
with high selectivity and efficacy in vivo (63). Similarly, doxorubicin encapsulated 
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DOTAP nanoparticles functionalized with DNA-based aptamer demonstrated a 
significant reduction in tumor growth in a tumor xenograft model (64). RNA- 
based aptamers have also been developed which can selectively bind to the T 
cell factor 1 and beta catenin in colon cancer cells (65-67). Locked nucleic acid- 
modified aptamers (LNA) used in iron oxide saturated lactoferrin nanocarriers 
demonstrated improved survival rate in colon cancer xenograft (68). RNA-A10 
aptamer PMSA (prostate specific membrane antigen) has also been reported for 
better therapeutic efficacy (69-71). 
Protein/peptides  
A variety of proteins/peptides have been investigated for tumor targeting. 
Several endogenous proteins which bind specifically to cell surface receptors 
have been used for targeting purposes (72). For example, transferrin, a protein 
involved in transport of iron, binds specifically to transferrin receptors which are 
overexpressed in variety of malignancies. Choi et al. showed that transferrin 
decorated PEGylated gold nanoparticles accumulated specifically in cancer cells 
avoiding nonspecific transport of nanoparticles to the healthy cells (73, 74). 
Muthu et al. demonstrated the enhanced efficacy of transferrin-functionalized 
vitamin E-based micellar nanosystems in MDA-MB 231 breast cancer cells (18). 
Jain et al. showed that transferrin-based nanosystems improved the antitumor 
activity against breast cancer cells (21). Krishna et al. developed a unique 
transferrin receptor targeting using apotransferrin protein as drug carrier for 
nanoparticles (75).  
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In addition to proteins, various peptides have also been used as targeting 
ligands, which are specific to the receptors overexpress on tumor cells. In order 
to find the best suitable peptide for targeting ligand, several peptide phage 
display libraries are available for identification of specific targeting ligands (76). A 
tumor homing penta-peptide CREKA that recognizes fibrin-associated plasma 
protein has been used as a targeting ligand on iron oxide nanoparticles and 
liposomes (77). Also penta-peptide LFC-131, an antagonist for CXCR4, a 
chemokine responsible for majority of inflammatory related cancers, has been 
used as a targeting ligand on polymeric nanoparticles for targeting CXCR4 
overexpressed in cancer cells (78). Peptides have also been reported for the 
receptor proteins viz. interleukin 11 receptor α (IL-11Rα) and 78 KDa glucose-
regulated protein (GRP78) in prostate and breast tumors (79-81). Among the 
different peptides, RGD peptide is a commonly used targeting ligand, which 
selectively binds to αvβ3, αvβ5 integrin (angiogenesis markers) overexpressed in 
endothelial and smooth muscle cells of tumor blood vessels. In an earlier 
investigation by Danhier et al. (2009) RGD-decorated paclitaxel-loaded 
nanoparticles demonstrated significantly enhanced tumor growth inhibition and 
prolonged animal survival (82). RGD-conjugated PLGA NPs have also shown 







Small molecules with molecular weight less than 500 Da are a promising 
class of targeting ligands because of their small size, low cost of synthesis, and 
high stability. Pomper et al. identified small hydrophilic molecules from urea-
based PMSA inhibitors which specifically target PMSA receptor overexpressed 
on the surface of prostate cancer cells (84). Chandran et al. developed 
docetaxel-encapsulated PLA/PCL-based targeted nanoparticles using PMSA as 
a targeting moiety (85). This moiety proved to be an efficient targeting ligand for 
the uptake of nanoparticles by PMSA-overexpressing cells. This small molecule 
is also used as a targeting ligand for the development of a novel polymeric 
nanoparticle BIND-014, composed of biodegradable hydrophobic PLA polymeric 
core and hydrophilic PEG. This is the first targeted- and controlled-release 
polymeric nanoparticle to reach clinical phase I trials for cancer chemotherapy 
(86). 
Among the different targeting strategies, vitamins are another class of 
molecules widely investigated for tumor targeting. The vitamins employed for 
targeting include folate, vitamin B12, thiamine, and biotin. The principal 
advantages associated with vitamins, particularly folic acid, include stability (both 
on the shelf and in the body), relative cost (low), lack of toxicity and 
immunogenicity, and wide flexibility for diverse chemical reactions (87). Folic acid 
has been widely investigated as a ligand in targeted drug delivery (88-90). Folic 
acid has high affinity for folate receptors which are over expressed in many types 
of solid tumors such as ovarian, lung, uterine, breast, head and neck cancers 
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(91). Besides the different tumors, folate has also been used as targeting ligand 
for delivery of many drug conjugates and delivery systems including liposomes, 
polymeric NPS through folate receptor mediated endocytosis (92). Folic acid- 
functionalized PLGA nanoparticles and deoxycholic acid-o-carboxymethylated 
chitosan-folic acid micelles have shown enhanced efficacy of doxorubicin and 
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Bioconjugation for surface-functionalization of nanocarriers 
In spite of the availability of a wide variety of targeting ligands, surface 
functionalization remains a challenge. The major requirement for surface 
functionalization is the presence of a targeting ligand on the NPs surface until the 
active load is delivered to the target site. To make the functionalization stable 
over the NP surface, a conjugation strategy that covalently links the ligands over 
the surface of the NPs by using simple chemistry was established (102, 103). 
The selection of the appropriate conjugation strategy is an important step, as the 
chemicals used for the conjugation may affect the targeting ligand during the 
process of conjugation (104). The most commonly used covalent conjugation 
approaches are through amide linkages, which link carboxyl group to amine 
using carbodiimide chemistry. It occurs by activation of carboxylic group present 
on the NP surface by EDC (1-ethyl-3-(3-dimethyl amino propyl) carbodiimide and 
NHS (N-hydroxysuccinimide) forming reactive intermediate which couples with 
amine groups present in targeting ligand. 
The chemical conjugation approach has been reported by Kocbek et al. to 
functionalize the PLGA NPs by using Mb as targeting ligand and by Acharya et 
al. who developed the nanoparticle bioconjugate by using epidermal growth 
factor (EGF) as A targeting ligand (105, 106). In addition to the use of carboxylic 
and amino groups, thiol functional groups have also been reported to form 
disulfide bonds for surface functionalization (107). Thiol group can react with 
other thiol group to form disulfide bond and also react with maleimide group to 
form thioether groups. Shaik et al. used the similar concept of forming disulfide 
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bond to conjugate anti-My9 antibody to stealth liposomes (107). Similarly, several 
other reports also demonstrated disulfide bond formation as a conjugation 
strategy between maleimide processing NPs and thiol-bearing ligands and vice 
versa (83, 104, 108). The highly specific, non-covalent reaction between avidin 
and biotin has been used to functionalize avidin containing liposomes with 
biotinylated antibodies (109). Other reaction complexes with streptavidin and 
neutravidin are also in public domain for conjugation (110). Although these non-
covalent binding techniques are available, the immunogenic reactions due to the 
source of avidin make this approach the second choice after covalent 
conjugation (111). 
‘Click’ chemistry is another interesting technique to conjugate targeting 
moieties to NPs (112). The use of click reactions became prevalent because of 
their high efficiency, specificity, ease of availability of reagents, low nonspecific 
binding, and physiological stability as compared to traditional crosslinking 
carbodiimide chemistry. Click chemistry is a single step reaction carried out 
under mild conditions in aqueous solutions producing high yield of product. It 
involves reaction between azide and alkyne under various conditions and the 
major classes of reactions involved are cooper-catalyzed azide-alkyne 
cycloaddition (CuAAC), Strain- promoted azide-alkyne click chemistry (SPAAC) 
and Tetrazine-trans-cyclooctene (TCO) ligation (113, 114). Koo et al. have 
reported the biorthogonal copper free click chemistry for tumor targeted delivery 




Exosome-mediated drug delivery as an emerging nanomedicine approach 
Exosomes are lipid bilayer biological nanoparticles secreted by all the 
cells in the body, present in almost all the body fluids, and play an important role 
in cell–to-cell communication (116-119). Exosomes are emerging as potential 
drug delivery nano vehicle (Figure 4). Exosomes have the advantages of being 
less immunogenic and showing better biological tolerability and cellular 
internalization compared with synthetic NPs (118, 120-122). There is a growing 
interest in exploiting these biological NPs for delivering chemotherapeutics and 
genetic material to the tumor site. With this growing interest, surface 
functionalization of exosomes for selective delivery of chemotherapeutics and 
siRNAs to cancer cells have been reported (123-125). Exosomes isolated from 





Figure 4. Diagram depicting the structure of exosome carrying lipid, DNA, RNA 
and protein (Source: With permission from Munagala et al., 2016 Bovine milk 












































































The field of exosomes as NPs is rather young and its use as a nanocarrier 
to deliver  cytotoxic drugs and phytochemical compounds has recently been 
explored with encouraging results  (126, 127, 129, 130, 137-139). For example, 
Tian et al., 2014 and Srivastava et al., 2016 reported enhanced efficacy of 
doxorubicin exosomal formulations (129, 138). Moreover, some studies have 
shown enhanced therapeutic efficacy of cytotoxic drugs and natural compounds 
while encapsulating these compounds in exosomes (127, 130, 131, 137, 139). 
Saari et al. showed that cytotoxic effect of paclitaxel to prostate cancer cells 
increased when encapsulated in exosomes (131). Milk derived exosomes have 
been reported to enhance therapeutic response of withaferin A (126) and 
celestrol (127), as well as to enhance the stability and therapeutic response of 
anthocyanidins (139) in various cancers. Zhuang et al. showed that the 
exosomal formulations of curcumin inhibited LPS-induced inflammation in a 
mouse model compared with  free curcumin and reported their positive effects 
against brain tumor when given through intranasal route (137).  
Due to their high complexity and variable composition, the cell specificity 
of these exosomes is not predictable, leading to non-specific targeting. Such off- 
target effects can be minimized through active targeting by functionalizing 
extracellular vesicles with targeting ligands. Exosomes are functionalized in 
several ways by decorating with specific ligands to improve the targeting ability 
(129, 140, 141). Folic acid-functionalized milk-derived exosomes were shown to 
enhance the therapeutic efficacy of withaferin A against lung cancer in vitro and 
in vivo (126). The peptide i-RGD, which is specific to the αvβ3 integrin receptor 
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that overexpressed in cancer cells, has been reported to fuse to the exosomal 
membrane proteins and lipids, i.e., Lamp2b and glycosylphosphatidylinositol 
(142). Alvarez et al. showed siRNA delivery to mouse brain by functionalizing 
exosomes with RVG peptide by fusing with Lamp2b exosomal membrane 
protein. These RVG exosomes could bind to specific receptor overexpressed in 
brain tumors. Tian et al. used the same mechanism to deliver doxorubicin to 
breast cancer cells (129). Chemical conjugation techniques, similar to those 
used for NPs, have also been used for the functionalization of exosomes (143).  
Kooijmans et al. reported a post insertion technique for exosome 
functionalization. In this technique, EGFR nanobody-conjugated PEG 
phospholipid micelles were mixed with extracellular vesicles derived from Neuro 
2A cells (143). Click chemistry has also been used for making functionalized 
exosomes (144). 
Clinical status 
To date only a handful of nanoformulations are FDA approved and 
available for clinical use. Liposomal formulations like DoxilR, Myocet, 
DaunoXome, Depocyt, polymeric nanoparticles such as AbraxaneR, and 
polymeric micelles like Glenexol-PM are FDA approved. The majority of the FDA-
approved nanomedicines were developed based on passive targeting which 
utilizes the EPR effect, due to the leaky vasculature of the tumor. There are 
certain functionalized nanoformulations which have been specifically designed to 
undergo ligand-mediated targeting selective to tumor site. The clinical status of 
novel nanoformulations has been summarized in Table 4.  
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MCC-465 is a novel PEGylated liposomal formulation encapsulating 
doxorubicin tagged with human monoclonal antibody fragment F(ab’)  in Phase I 
clinical trial against metastatic stomach cancer (145). Recently, a PEGylated 
liposomal formulation of doxorubicin functionalized with F (ab’) fragment of 
antibody cetuximab (C225) was approved for clinical use (146). Liposomal 
formulation of oxaliplatin (SGT53) functionalized with single chain antibody 
fragment (TfRscFv) as targeting ligand is in a Phase I of clinical trial (147). 
Cyclodextrin-based nanoparticles (CALAA-01) is the first nanoformulation in 
clinical trial for the siRNA delivery to tumor site (148). Heat-activated PEGylated 
liposomes containing doxorubicin (Thermodox) is in Phase III clinical trial for 
treating liver cancer (149). Similar to liposomal formulations, some polymeric 
nanoparticles are at different stages of clinical trials. PEG-poly(aspartic acid) 
polymeric nanoparticles like NK 105 and NK 911, and PEG-cyclodextrin 
nanoparticles like CRLX101 are in phase I and phase II clinical trials (150). 
Targeted-polymeric nanomedicines like BIND-014, PEGylated PL(G)A docetaxel 
formulation has completed the phase I and is now in Phase II clinical trials (86). 
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The rapid advances in the field of nanomedicine have created a new 
trend and opened the doors for the development of different tools and strategies 
for anticancer therapy. Nanoparticle drug formulations have the potential to 
overcome the limitations of conventional chemotherapy by their ability to 
selectively target cancer cells over healthy tissue. Properly designed 
nanoparticles have the ability to accumulate in tumors either by passive or 
active targeting and enhance the cytotoxic effects of antitumor agents. Several 
nanoformulations of anticancer drugs are being evaluated in phase II/III clinical 
trials while relatively few have been approved for clinical use. Nanotechnology 
provides an opportunity to revisit and reformulate the drugs that have been 
shelved due to poor oral bioavailability, lack of selectivity to the desired target, 
or extreme toxicity. Biological nanoparticles, i.e., exosomes, provide another 
promising avenue for delivery of small and macromolecules. Nevertheless, the 
field of nanotechnology has the potential to shift the paradigm of treatment for 






         In spite of various advantages of NPs, efficient delivery of drugs has never 
been completely achieved due to lack of ideal drug delivery system. The major 
limitations being low biocompatibility and toxicity. Their characterization, cost, 
scalability, inability to evade host immune system, limited circulation time and 
safety issues still remain as a challenge (151). Exosomes seem to overcome 
several of the limitations associated with the conventional nanoparticles. They 
have ability to target tissues by utilizing the intrinsic mechanisms of extracellular 
vesicles. Exosomes are biocompatible, potentially nontoxic, less immunogenic, 
and provide desired long-term safety for therapeutic use. They have the natural 
ability to carry nucleic acids and other therapeutic molecules cross membranes 
that are difficult to cross such as the blood brain barrier (BBB). There are 
several recent studies published which isolated exosomes from different 
sources like biological fluids and cell culture media using variety of strategies 
(129, 142, 152). However, they still suffer from biocompatibility and scalability 
issues. Particularly cost–effective, mass-scale production, drug loading and 
targeting strategies are limitations, which lessen the throughput of this field. 
More recent development of milk exosomes seem to overcome many of these 
limitations (126-128, 139). However, immune-compromised subcutaneous 
xenograft mouse models used in these studies have some limitations as the 
formulations are not being tested in tumor microenvironment.  
Tumor growth is complex and heterogeneous microenvironment consist of 
different immune cells. So it is crucial to develop nanoformulations that can 
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adapt to the microenvironment and improve the selective targeting to tumors. 
Apart from few, most of the formulations have not yet been in clinic considering 
this aspect. The studies need to be performed with more sophisticated 
humanized mouse models (i.e., patient-derived tumor xenograft models) and 
also in different immunocompetent animal models (such as spontaneous tumor 
models, carcinogen-mediated tumor models) which take tumor 
microenvironment into consideration. This will better match the system of human 
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